Advanced searches left 3/3

Colorectal Cancer - Crossref

Summarized by Plex Scholar
Last Updated: 19 August 2022

* If you want to update the article please login/register

Clinical and Basic Evaluation of the Effects of Upregulated TNFAIP3 Expression on Colorectal Cancer

To determine the TNFAIP3 and nuclear factor u03baB protein expressions in colorectal cancer tissue and to investigate the association of these proteins with CRC's clinical pathological characteristics. Cell transfection, CCK8 measurement system, transwell experiment, and western blot experiments are among the cell culture experiments that have been used for cell culture: cell transfection, cell transfection, CCK8 detection method, and western blot experiment. Investigate the TNFAIP3 gene in CRC cells to determine the impact of increased TNFAIP3 expression on CRC cell proliferation, migration, and migration. We used the tumor tissue of 39 CRC patients as our experimental samples in a clinical study. In 20 experimental and 20 control samples, we also investigated the TNFAIP3 and NFu03baB protein expressions, determining potential correlations between these two proteins and CRC pathological characteristics. We established CRC cell lines with elevated TNFAIP3 expression and then randomly divided the cells into three groups, namely, TNFAIP3, NS, and Con groups, for basic experiments. CRC migration capabilities and cell proliferation were determined by using the transwell and CCK8 methods, respectively. Protein expression in the three groups was also determined by western blot analysis to determine protein expression in the three groups. The TNFAIP3 and NF-u03baB protein expressions were strongly linked to lymph node metastasis and tumor differentiation, according to tumor differentiation. TNFAIP3 protein expression, cell proliferation, invasion, and migration were all significantly higher in the TNFAIP3 group during the basic experiment, relative to the Con and NS groups. Patients with elevated malignant degree, metastasis, and TNFAIP3 protein expression in CRC tissues were correlated with elevated malignant degree, metastasis, and TNFAIP3 protein expression in patients with a high malignant degree and metastasis.

Source link: https://doi.org/10.1155/2022/1263530


Colorectal cancer risk in association with colorectal cancer as a second malignancy in relatives: a nationwide cohort study

We wanted to determine if and to what extent a family's CRCa-2 history was correlated with an elevated risk of CRC disease. CRC's RRs of CRC for one FDR diagnosed with CRCa-1 and CRCa-2 were respectively 1. 72 and 1. 50, respectively; the former RR was less than the former; but no difference was made after adjusting the age of diagnosis of CRC in FDR and family relationship. Individuals with CRCa-2 are at a higher risk of CRC, while those with CRCa-1 are less likely, depending on the ages of diagnosis of CRC in FDR and family relations.

Source link: https://doi.org/10.1186/s12885-022-10000-z


A comprehensive algorithmic dissection yields biomarker discovery and insights into the discrete stage-wise progression of colorectal cancer

Colorectal cancer remains a common disorder with a high incidence of disease, heterogeneity in appearance, and no definitive cure. Against this backdrop, renewed attempts to establish the genetic causes of colorectal cancer progression are crucial. Early-stage detection of cancer can enhance treatment's success as well as prognosis. Here, we've developed a sophisticated computational workflow aimed at finding the specifics stagewise genetic causes of colorectal cancer progression. We created stage-specific linear models and compares to determine stage-specific differentially expressed genes using the TCGA COADREAD expression and clinical metadata to determine stage-specific differentially expressed genes. Stage-specific differentially expressed genes with a consistent trend of expression across the stages were identified as stage-specific biomarkers. Many classes of biomarkers were found in the research, which may have served in signature panels for early-stage colorectal cancer diagnosis as well as establishing therapeutic protocols.

Source link: https://doi.org/10.1101/2022.08.16.22278877


Perceived Religiousness is Protective for Colorectal Cancer: Data from the Melbourne Colorectal Cancer Study

As part of a large, comprehensive population-based study of colourectal cancer incidence, aetiology, and survival conducted in Melbourne, Australia, the perceived or self-reported degree of u2018religiousness (u2019) was determined by a questionnaire among 715 colorectal cancer patients and 727 age-matched community controls. Although self-reported or perceived u2018religiousnessu2019 was compared to 52 months in those self-reported as being u2018non-religious,'u2019, this disparity was not statistically significant.

Source link: https://doi.org/10.1177/014107689308601112


A Survey of Industries and Colorectal Cancer Screening of Employees in the East Midlands of England

Examine a number of companies in the East Midlands of England who were able to enrol their employees in a scheme to detect colorectal cancer by faecal occult blood testing was investigated. When asked whether they would have a list of their employees over the age of 40 years and encourage a research team to give a 15 minute talk at the workplace, Company executives were asked if they would give a list of their employees over the age of 40 years and encourage a research team to hold a 15 minute interview.

Source link: https://doi.org/10.1177/014107689308601009


Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Following therapy withdrawal, we previously reported that RAS, BRAF, and EGFR mutant alleles, which appear in circulating tumor DNA during EGFR blockade's suppression of EGFR blockade, disappear. We hypothesized that detecting resistance mutations in blood could help with subsequent anti-EGFR antibodies therapy. CHRONOS, an open-label, single-arm phase 2 clinical trial that utilized blood-based detection of RAS/BRAF/EGFR mutations in order to create a panitumab-free anti-EGFR rechallenge. Patients with tissue-RAS WT tumors following a previous treatment with anti-EGFR-based regimens in CHRONOS underwent an interventional ctDNA-based screening. These clinical findings favorably compare with current third-line therapies, showing that interventional liquid biopsies can be safely and effectively used in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC.

Source link: https://doi.org/10.1038/s41591-022-01886-0


Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations

Abstract The precise identification of immunopeptides from small biopsies of clinical tissues by mass spectrometry is still difficult, given the lack of understanding of human leukocyte antigen peptides. On average, 42. 9 mg of normal and tumor colorectal tissues from identical patients were tested by DIM-MS for immunopeptidomics analysis, and on average, 4921 immunopeptides were found. Since the direct detection of neoantigens from tumor tissue, we suspect that more potential neoantigens had yet to be identified, we screened cell lines with known oncogenic KRAS mutations and found 2 more neoantigens that carry KRAS-G12V.

Source link: https://doi.org/10.1038/s42003-022-03807-w


Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers

The main hypothesis of this study is that gene expression profiles incorporating both tumor antigenicity and a pre-existing adaptive immune response can be used to develop specific immune-related BRAF mutant colorectal cancers in order to identify actionable biomarkers predictive of immune response to immunotherapy. In MSI tumors compared to MSS cases, the Antigen Processing Machinery signature was not significantly expressed in MSI tumors. Immun checkpoint blockade may be very helpful in broadening the population of patients with BRAF-CRCs who can benefit from immune checkpoint blockade.

Source link: https://doi.org/10.3390/cancers14163951


Pro-tumorigenic role of type 2 diabetes-induced cellular senescence in colorectal cancer

Since age-related cell death and type 2 diabetes have been identified as risk factors for CRC proliferation, the finding that type 2 diabetic patients have an elevated circulating number of senescent cells raises the question of whether CRC tumorigenesis is aided by premature cell senescence can be attributed to CRC tumorigenesis. In this article, we will explore the reasons by which T2D-induced cellular senescence and the role of type 2 diabetes-induced cell senescence in the pathogenesis and progression of colorectal cancer.

Source link: https://doi.org/10.3389/fonc.2022.975644


The Characteristics of Hereditary Colorectal Cancer Syndromes by Population Screening

Because of its frequent occurrence and severe prognosis, colorectal cancer is a common medical issue. Population screening was carried out in Valka county, determining family cancer history by questionnaire. Hereditary colorectal cancer syndromes were identified by internationally recognized medical studies. The following population frequencies were established: hereditary non-polyposis colorectal cancer, 0. 05 percent; suspected HNPCC and familial colorectal cancer, 0. 10 percent; 0. 10 percent. The cancer burden among blood relatives of the affected families varied from 15. 5 to 11%. The mean age of colorectal cancer diagnostics was 53. 7 to 2. 0 years. A large number of cases have been reported. The population frequencies of hereditary colorectal cancer syndromes matched to a considerable number of cases.

Source link: https://doi.org/10.2478/v10163-011-0001-5

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions